Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

Background Although randomized trials provide a high level of evidence regarding the
efficacy of non-vitamin K oral anticoagulants (NOACs), the results of such trials may differ …

Background: The J-RHYTHM Registry 2 was a multicenter, prospective observational study
that extended the follow-up period of the J-RHYTHM Registry in order to investigate long …

Introduction There are a paucity of real-world data examining effectiveness and safety of non-
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …

Objectives: There is scarce evidence comparing novel oral anticoagulants (NOACs) with
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …

Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as
alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Introduction: Choosing between different non-vitamin K antagonist oral anticoagulants
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …

Background and Purpose—Limited evidence exists on the effectiveness and safety of
warfarin and all 4 available non-vitamin K antagonist oral anticoagulants (NOACs) from …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …